Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Vassil Traykov Added: 10 months ago
EHRA 2025 - What advice does Dr Vassil Traykov provide for the best practice when treating CIED-related infections?Dr VassilTraykov (Tokuda Hospital Sofia, Sofia, BG) joins us on-site at EHRA Congress 2025 to discuss antimicrobial treatment of CIED-related infections, covering the current treatment landscape, recent guideline recommendations and his hopes for the future management of CIED-related… View more
Author(s): Vivek Reddy Added: 9 months ago
HRS 25 - First-in-human data from the FIH VCAS trial suggests the FieldForce Ablation system can effectively create transmural ablation lesions in patients with scar-related ventricular tachycardia (VT), with an 80% freedom from VT and ventricular fibrillation rate at 6 months.We are joined by Dr Vivek Reddy (Mount Sinai Hospital, New York, US) to discuss the findings from the prospective, first… View more
Start date: Aug 27, 2023 End date: Aug 27, 2023
Radcliffe Medical Education present a satellite symposium entitled ‘Implementing Heart Failure Guidelines with Collaborative Care’ at the ESC Congress 2023 in Amsterdam, NL. Join us in the Riga Lecture Room, or online, on Sunday 27 August 2023, from 12:45 to 13:45 CEST. This session, chaired by Prof Carolyn Lam (National Heart Centre Singapore, SG), provides an excellent opportunity for… View more
Author(s): Elaine Wan , Majd Al Deen Alhuarrat Added: 1 year ago
In the latest episode of Arrhythmia Academy's Journal Club, Dr Elaine Wan (Columbia University, New York, NY, US) and Dr Majd Al Deen Alhuarrat (Albert Einstein College of Medicine, New York, NY, US) discuss the in-hospital outcomes and complications of using leadless pacemakers and traditional transvenous pacemakers.Dr Alhuarrat provides a concise history and background of transvenous and… View more
Author(s): Christian Sohns , Added: 2 years ago
ESC 2023 — We are joined onsite by Prof Christian Sohns and Prof Philipp Sommer (Heart and Diabetes Centre, Bad Oyenhausen, DE) to discuss the findings from the CASTLE-HTx trial (NCT04649801). CASTLE-HTx (Heart and Diabetes Center North-Rhine Westfalia) aimed to determine if atrial fibrillation ablation has beneficial effects on mortality in patients with end-stage heart failure, who are… View more